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When endothelin-1 was discovered it was hailed as the prototypical
endothelium-derived contracting factor (EDRF). However, over the years
little evidence emerged convincing this author that the peptide actually
contributes to moment-to-moment changes in vascular tone elicited by
endothelial cells. This was attributed to the profound inhibitory effect of
nitric oxide (NO) on both the production (by the endothelium) and the
action (on vascular smooth muscle) of endothelin-1. Hence, at least in
the author's mind, endothelin-1 was likely to initiate acute changes in
vascular diameter only under extreme conditions of endothelial
dysfunction when the NO bioavailability is considerably reduced if not
absent. This lecturewill surveymore recent ﬁndings and decidewhether
this concept should be revised, or maybe not…
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